Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients

Nyangwara, Vincent; Mazhindu, Tinashe; Chikwambi, Zedias; Masimirembwa, Collen; Campbell, Thomas; Borok, Margaret; Ndlovu, Ntokozo

doi:10.1111/bcp.15659

Cited by 3 publications

(3 citation statements)

References 61 publications

(114 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With respect to the genetic factors, the following are currently under investigation with potentially promising outcomes: polymorphisms in p53 (rs1042522) [ 313 , 314 ], NOS3 (rs1799983), NADPH oxidase (rs4673), GPX1 (rs1050450) [ 313 ], RARG [ 37 , 315 ], POLRMT [ 316 ] DPYD [ 317 ] and ABCC1 [ 318 ]. Interestingly, Varkoly et al, 2022 [ 319 ], demonstrated for the first time that circulating RNA virus gene sequences (e.g., influenza orthomyxovirus) were detected in the blood samples of patients with hematological malignancies or breast cancer and were associated with myocarditis and lower LVEF in response to chemotherapy.…”

Section: Resultsmentioning

confidence: 99%

New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review

Alexandraki

Papageorgiou

Zacharia

et al. 2023

Cancers

View full text Add to dashboard Cite

Cardiotoxicity induced by breast cancer therapies is a potentially serious complication associated with the use of various breast cancer therapies. Prediction and better management of cardiotoxicity in patients receiving chemotherapy is of critical importance. However, the management of cancer therapy-related cardiac dysfunction (CTRCD) lacks clinical evidence and is based on limited clinical studies. Aim: To provide an overview of existing and potentially novel biomarkers that possess a promising predictive value for the early and late onset of CTRCD in the clinical setting. Methods: A systematic review of published studies searching for promising biomarkers for the prediction of CTRCD in patients with breast cancer was undertaken according to PRISMA guidelines. A search strategy was performed using PubMed, Google Scholar, and Scopus for the period 2013–2023. All subjects were >18 years old, diagnosed with breast cancer, and received breast cancer therapies. Results: The most promising biomarkers that can be used for the development of an alternative risk cardiac stratification plan for the prediction and/or early detection of CTRCD in patients with breast cancer were identified. Conclusions: We highlighted the new insights associated with the use of currently available biomarkers as a standard of care for the management of CTRCD and identified potentially novel clinical biomarkers that could be further investigated as promising predictors of CTRCD.

show abstract

Section: Resultsmentioning

confidence: 99%

New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review

Alexandraki

Papageorgiou

Zacharia

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Future directions in PGx are also discussed with a focus on new clinical targets, methodologies and analysis approaches 3 . Bearing this in mind, Nyangwara et al provide insights on the prevalence of doxorubicin‐induced cardiotoxicity in black Zimbabwean breast cancer cohort and attempt to evaluate the predictive value of genetic biomarkers for cardiotoxicity 4 …”

Section: Figurementioning

confidence: 99%

“…3 Bearing this in mind, Nyangwara et al provide insights on the prevalence of doxorubicin-induced cardiotoxicity in black Zimbabwean breast cancer cohort and attempt to evaluate the predictive value of genetic biomarkers for cardiotoxicity. 4 Mechanistic insight into drug toxicity can be obtained also by using the data from metabolomic analysis to identify a drug candidate's off-targets; thus, metabolomics may also help to lay another pathway toward drug safety. Lim et al have identified glycine, hippuric acid sulfate, 3-hydroxydecanedioc acid and suberate as predictive biomarkers of predisposition to cisplatin-induced acute kidney injury (AKI) and speculated that metabolites indicative of mitochondrial dysfunction may serve as early markers of subclinical AKI.…”

mentioning

confidence: 99%

Past, present and future of drug safety: Editorial

Rieder,

Belančić

2024

Brit J Clinical Pharma

View full text Add to dashboard Cite

For most of recorded history, drug therapy was primarily conducted based on traditional beliefs and anecdotal reports with agents that were often ineffective, frequently not expensive and frequently fairly innocuous. This changed dramatically with the Therapeutic Revolution when the discovery in 1935 that bacterial infection could be cured with specific therapy produced paradigm changing effects on health care and medical practice. 1 The excitement over the use of sulfanilamide therapy was however soon muted with the Elixir of Sulfanilamide Tragedy. 2 Over the following decades, as the benefits of drug therapy have increasingly evolved, so has our appreciation of the potential for drug harms (Figure 1).Given that new opportunities and challenges in drug safety field are constantly arising, some current insights and future directions deserve to be outlined according to the evidence-based medicine approach. Data arising from meta-analyses of observational studies reported that 5%-10% of hospital admissions were caused by adverse drug reactions and that approximately half of those hospitalizations could be prevented. Thus, in this issue of the British Journal of Clinical Pharmacology, we are considering the theme of drug safety with a number of manuscripts exploring drug harms and their detection.An already well-established but still growing area in drug safety is pharmacogenetics (PGx), which has the potential as a component of Not applicable.

show abstract

BCSNP-ML: A Novel Breast Cancer Prediction Model Base on LightGBM and Estrogen Metabolic Enzyme Genes

Zheng,

Geng,

Yan

et al. 2024

Lecture Notes in Electrical Engineering

View full text Add to dashboard Cite

Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients

Cited by 3 publications

References 61 publications

New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review

New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review

Past, present and future of drug safety: Editorial

BCSNP-ML: A Novel Breast Cancer Prediction Model Base on LightGBM and Estrogen Metabolic Enzyme Genes

Contact Info

Product

Resources

About